The New Frontier in HIV Pre-exposure Prophylaxis: Lenacapavir Update

Tuesday, October 14, 11:30am - 12:30pm (EDT)

Link:

Time shown in -04:00 America, New York

In the ongoing search for new methods to address the HIV epidemic, the development of lenacapavir for HIV prevention is a major step forward. Findings from research studies has shown that twice-yearly injection of long-acting lenacapavir provides protection against HIV infection. This discovery offers great promise in advancing our progress towards ending AIDS as a public health threat.

In this special lecture, Moupali Das, MD, MPH, vice president, Clinical Development, HIV Prevention and Virology Pediatrics, at Gilead Sciences, will provide an update on research findings on lenacapavir for HIV prevention. Her talk will cover the status of the PURPOSE 1-5 studies, review ongoing implementation science studies, and look at the pipeline for pre-exposure prophylaxis (PrEP) at a pivotal moment for the global HIV response

Please fill out the information below to register for the event.

Goingdone
Maybequestion_mark
Can't Goclear

Name

Confirmed

A confirmation email is on its way. Check your spam folder if it doesn't show up.

Add to Calendar 2025/10/14 11:30:00 2025/10/14 12:30:00 America/New_York The New Frontier in HIV Pre-exposure Prophylaxis: Lenacapavir Update In the ongoing search for new methods to address the HIV epidemic, the development of lenacapavir for HIV prevention is a major step forward. Findings from research studies has shown that twice-yearly injection of long-acting lenacapavir provides protection against HIV infection. This discovery offers great promise in advancing our progress towards ending AIDS as a public health threat.

In this special lecture, Moupali Das, MD, MPH, vice president, Clinical Development, HIV Prevention and Virology Pediatrics, at Gilead Sciences, will provide an update on research findings on lenacapavir for HIV prevention. Her talk will cover the status of the PURPOSE 1-5 studies, review ongoing implementation science studies, and look at the pipeline for pre-exposure prophylaxis (PrEP) at a pivotal moment for the global HIV response 722 West 168th Street, New York, 10032, NY, USA Hugh Siegel icap-communications@columbia.edu false 240

Response submitted

A confirmation email is on its way. Check your spam folder if it doesn't show up.

Response submitted

Thanks for letting us know.

722 West 168th Street, New York, 10032, NY, USA

Hugh Siegel, icap-communications@columbia.edu